Page 12 - Pnt O News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pnt o. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pnt O Today - Breaking & Trending Today
MetLife Investment Management LLC grew its holdings in shares of POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating) by 13.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 46,389 shares of the company’s stock after purchasing an additional 5,454 shares during the period. MetLife Investment Management LLC’s […] ....
POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating) – Investment analysts at Oppenheimer cut their FY2027 earnings per share (EPS) estimates for POINT Biopharma Global in a report issued on Monday, March 27th. Oppenheimer analyst J. Jones now forecasts that the company will post earnings per share of $0.21 for the year, down from their […] ....
POINT Biopharma Global (NASDAQ:PNT – Get Rating) issued its quarterly earnings results on Monday. The company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $1.79, MarketWatch Earnings reports. The business had revenue of $226.58 million during the quarter, compared to analyst estimates of $260.00 million. POINT Biopharma […] ....
POINT Biopharma Global (NASDAQ:PNT – Get Rating) announced its earnings results on Monday. The company reported $1.53 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $1.79, MarketWatch Earnings reports. The business had revenue of $226.58 million for the quarter, compared to analysts’ expectations of $260.00 million. POINT Biopharma Global Stock […] ....
POINT Biopharma Global (NASDAQ:PNT – Get Rating) announced its earnings results on Monday. The company reported $1.53 EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $1.79, MarketWatch Earnings reports. The company had revenue of $226.58 million during the quarter, compared to analysts’ expectations of $260.00 million. POINT Biopharma Global Stock Performance POINT […] ....